View Older Stories View More Recent Stories

Feb 12, 2021 01:00AM The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Feb 9, 2021 05:15PM La FDA approuve Libtayo® (cemiplimab-rwlc), premier médicament d’immunothérapie indiqué pour le traitement des patients atteints d’un carcinome basocellulaire au stage avancé
Dec 18, 2020 12:22PM Mylan (VRTS) Wins Summary Judgment in EpiPen Litigation Brought by Sanofi (SNY)
Nov 30, 2020 01:00AM Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Oct 26, 2020 08:00AM Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
Oct 16, 2020 08:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
Oct 13, 2020 05:56AM Regeneron (REGN) Reports Pivotal Ph. 3 Trial of Dupixent (dupilumab) Met Primary & All Key Secondary Endpoints, Significantly Reducing Severe Asthma Attacks in Children
Oct 13, 2020 01:00AM Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Sep 21, 2020 08:27AM Regeneron (REGN), Sanofi (SNY) Announce Late-breaking ESMO Presentation Shows Libtayo Monotherapy Increases OS in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Sep 21, 2020 08:25AM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 20, 2020 08:25PM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 18, 2020 03:05AM Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
Sep 14, 2020 06:12AM Regeneron (REGN) Reports Dupixent (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis
Sep 14, 2020 01:00AM FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
Sep 8, 2020 06:32AM Regeneron (REGN) SanoSNY) Reports New Results from Dupixent (dupilumab) Phase 3 Open-Label Extension Trial
Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 01:00AM Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
Jul 21, 2020 07:30AM Acerus Announces Addition of Chief Medical Officer
Jul 2, 2020 04:30PM Regeneron (REGN), Sanofi (SNY) Announce Kevzara Phase 3 U.S. Trial in COVID-19 Patients Did Not Meet its Primary and Secondary Endpoints
Jul 2, 2020 04:30PM Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Jun 23, 2020 06:17AM Sanofi (SNY), Translate Bio (TBIO) Report Collaboration Expansion to Develop mRNA Vaccines Across All Infectious Disease Areas
Jun 23, 2020 12:59AM Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
Jun 19, 2020 01:51PM UPDATE: Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Dupixent (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
Jun 19, 2020 01:51PM FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 19, 2020 07:32AM Regeneron (REGN), Sanofi (SNY) announce Dupixent approved in China for adults with moderate-to-severe atopic dermatitis
Jun 19, 2020 07:32AM Regeneron (REGN), Sanofi (SNY) Confirm Dupixent (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 19, 2020 07:30AM Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
May 29, 2020 08:00AM Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
May 26, 2020 11:41AM Regeneron (REGN), Sanofi (SNY) Announce FDA Approves Dupixent as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
May 26, 2020 11:40AM Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
May 26, 2020 05:54AM Regeneron (REGN) Reports Dupixent (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
May 22, 2020 06:25PM Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
May 5, 2020 01:00AM Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
Apr 27, 2020 07:01AM Regeneron (REGN) Reports Ph.3 Trial of Libtayo (cemiplimab) as Monotherapy for First-Line Advanced NSCLC Stopped Early Due to Highly Significant Improvement in OS
Apr 27, 2020 07:00AM Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
Apr 27, 2020 06:58AM Regeneron (REGN), Sanofi (SNY) U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara in Hospitalized COVID-19 Patients to Discontinue Lower-Dose, Continue Higher-Dose
Apr 27, 2020 06:58AM Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Apr 3, 2020 06:00AM Sanofi (SNY) Reports Dupixent (dupilumab) Phase 3 Data Shows Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Apr 3, 2020 01:00AM Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
Mar 30, 2020 09:55AM Regeneron (REGN) Gains After Treating First COVID-19 Patients Outside U.S. in Kevzara Trial
Mar 30, 2020 01:00AM Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Mar 27, 2020 05:53AM Translate Bio (TBIO), Sanofi Pasteur (SNY) Announce Collaboration to Develop a Novel mRNA Vaccine Candidate Against COVID-19
Mar 27, 2020 02:00AM Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
Mar 27, 2020 02:00AM Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19
Mar 16, 2020 08:02AM Sanofi (SNY), Regeneron (REGN) begin global Kevzara clinical trial program in patients with severe COVID-19
View More Recent Stories View Older Stories